AlphAIAlphAI — Financial news for AI agents
tipranks.comOCT 282 min read$GMAB

Genmab Stock (GMAB) Soars Over 30% on Strong Phase 3 Results for the Company’s Head and Neck Cancer Treatment

Genmab (GMAB) shares surged 30.54% after announcing positive Phase 3 trial results for petosemtamab combined with pembrolizumab in treating head and neck cancer. The treatment showed a 50% reduction in death risk. The company plans to seek regulatory approval. GMAB stock has gained 87.73% year-to-date and 54.3% over the past year. Analysts' average price target is $94.89, suggesting a 62.26% upside.

Original reporting
tipranks.com
Published Oct 28, 2026, 5:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 6:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$GMAB
Bullish
high confidence
Mentioned
$GMAB
Relevance
7/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

The interim Phase 3 results represent a pivotal milestone that could accelerate regulatory submissions and commercial rollout, driving near‑term price action.

02

Market read

First‑report Phase 3 data with strong survival benefit, causing a 30% stock surge; high relevance for traders seeking biotech catalyst plays.

03

What to watch

Regulatory timelines and potential competition from other PD‑L1 combos could temper upside.

Relevance 7/10Novelty 9/10Timing: today

Background

Genmab is a Denmark‑based biopharma focused on antibody therapeutics; the LiGeR‑HN1 trial tests its proprietary antibody petosemtamab with pembrolizumab.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab reported positive Phase 3 topline results for its petosemtamab‑pembrolizumab head‑and‑neck cancer combo, sending the stock up 30% on the day.

Expected impact

upward pressure as investors price in the survival benefit and potential regulatory approval.

Evidence & confidence

Phase 3 data are material for a biotech; the stock already rallied 30% on the news, indicating strong market reaction.

Market effects

Sector

Positive oncology trial data may lift sentiment for other head‑and‑neck cancer biotech peers.

Regional

European biotech indices could see modest gains as a Denmark‑based firm reports breakthrough data.

Global

Adds to the broader narrative of successful immuno‑oncology combos, supporting sector momentum.

Counterpoint

What could challenge this read

If the final analysis fails to confirm the interim benefit, the stock could face a sharp correction.

Key entities

  • company
    Genmab

    Denmark‑based biopharmaceutical company developing antibody therapies.

  • person
    Everett Vokes, MD

    Chair, Department of Medicine, University of Chicago Medicine, quoted on trial significance.

Read at source← All news

StoryGenmab reports Phase 3 trial shows 50% death‑risk reduction for head‑and‑neck cancer combo

Also covered by

3 outlets

Related articles

OCT 28
$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

rttnews.com2 min
OCT 28
$GMABHigh

GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know

Genmab (GMAB) stock rose nearly 30% to an all-time high after positive Phase 3 trial results for its experimental head and neck cancer treatment, Petosemtamab, combined with Merck's Keytruda. The trial met primary goals, showing a 50% reduction in death risk and tripled tumor response odds. The company also reported positive Phase 3 results for its ovarian cancer drug, Rina-S, last week. Retail sentiment on Stocktwits turned bullish.

finance.yahoo.com2 min
OCT 28
$GMABHighAI 8/10

Genmab (GMAB) Stock Surges As Rina-S And Petosemtamab Data Fuel Bull Run

Genmab A/S (GMAB) stock surged 28.9% on October 28, 2026, following positive data for its oncology drugs Rina-S and petosemtamab. The company reported strong Phase 3 results for Rina-S in ovarian cancer and promising Phase 2 data for petosemtamab in colorectal and head and neck cancers. Analysts upgraded GMAB, citing the potential of these drugs, with JPMorgan raising its price target significantly. GMAB's revenue is approximately $21.53B, with a P/E ratio of 155.11.

timothysykes.com2 min
OCT 28
$GMABHighAI 9/10

Genmab reports 50% lower death risk in Phase 3 trial

Genmab reported that its petosemtamab combination reduced the risk of death by 50% in a Phase 3 head-and-neck cancer trial, meeting both primary endpoints. The study involved 699 patients. Genmab's shares rose 15.22% to $51.47 on Wednesday. The company plans to discuss results with global regulators.

mugglehead.com2 min